DEWIZ
10.8.2021 11:51:08 CEST | Business Wire | Press release
deWiz’s Board of Directors, including co-founders Christian Bergh and Markus Westerberg, have announced Laszlo Varga as deWiz’s new Chief Executive Officer, starting August 16. Varga will apply his extensive experience leading e-commerce businesses like Gents and EuroFlorist to deWiz’s go-to-market strategy in golf and help develop strategic extensions for deWiz’s technology with other sports and disciplines. As CEO, Varga will oversee the start-up’s transition to a comprehensive global strategy by aligning all aspects of deWiz businesses using his expertise across consumer products, digital marketing, and direct sales.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210810005498/en/
Debuting this summer, deWiz’s revolutionary wearable technology delivers groundbreaking instantaneous feedback and high-precision swing data that accelerates golfers’ pace of learning and adds consistency. deWiz’s introduction to the golf and business world has already created a “buzz” with it being described by Forbes as looking to bring a “jolt to the golf training aid market ;” being profiled in Sweden’s leading financial media, Dagens Industri ; and being featured in Sport Techie’s Startups series .
“On behalf of my co-founder Markus and the deWiz board, I am thrilled to have Laszlo join our journey as we strive to help golfers improve faster with our science-backed technology as their competitive edge. As I continue as Chief Operations Officer for deWiz and as a board member, it’s a testament to how much we’ve accomplished since founding the company to have attracted somebody of Laszlo’s caliber and business acumen to lead our global strategy moving forward,” said Christian Bergh, co-founder and COO of deWiz.
“I’m super excited and proud to join the deWiz team. The product is truly revolutionary in helping athletes improve their performance by combining neural science with instant feedback and unmatched data capture. There is nothing else like deWiz in the golf market and the feedback we've gotten from the early users is overwhelmingly positive. With my experience and understanding of global e-commerce and direct sales to consumers, I hope to contribute to the accelerated growth and success of this awesome company that is on the front edge of innovation," said Laszlo Varga, CEO of deWiz.
Varga has a strong background in multi-national e-commerce and direct-to-consumer sales. Prior to joining deWiz, Laszlo was the CEO of Gents, a brand and online retailer for male grooming products. Before joining Gents, Varga was the CEO of Euroflorist, Europe’s largest flowers by wire company where he had a long and successful career, serving previously as Chief Operations Officer and Online Director, heading the online transition of sales. Varga’s entrepreneurial spirit and busines building skillset is also relied upon as a board member for Gents, CoolStuff and BoneProx. Varga is based in Malmö, Sweden, where he has spent the majority of his professional career after graduating from San Diego State University and competing at an elite level in kayaking.
DEVELOPED BY EXPERTS, TESTED BY PROS: deWiz’s has been in development for more than five years and has attracted an impressive roster of ambassadors, including 2020 U.S. Open Champion Bryson DeChambeau, 10-time Major Champion Annika Sorenstam, 3-time Major Champion Vijay Singh, 2-time Major Champion Lydia Ko, 2016 Open Champion Henrik Stenson, 2019 Houston Open Champion Lanto Griffin and 2-time World Long Drive Champion Tim Burke. deWiz’s user-friendly app and wearable tech tracks the precise position of a golfer’s hands throughout their swing, providing a 3D analysis and delivering data showcasing Transition , Length of Backswing , Wedge Distance and Tempo . These unique deWiz data points provide measurable metrics that any avid golfer, teaching professional or world-class player can utilize to efficiently refine their swing. Currently for sale for 699 USD, deWiz is available across the United States, Canada, Europe, and South Korea (more markets opening regularly – visit the website for the latest updates). Please visit dewizgolf.com for more details on how to improve your swing faster or download the app to demo its features via Apple’s App Store or Google Play.
ABOUT deWiz
The deWiz golf training platform has been developed by former European Tour pro, PGA of Sweden certified instructor and motor learning author, Markus Westerberg, and entrepreneur and technology business leader Christian Bergh. As a Swedish developed and produced product, deWiz is focused on its mission to help golfers around the world elevate their enjoyment of the game through innovative technology that accelerates the pace of learning. deWiz’s revolutionary wearable technology delivers groundbreaking instantaneous feedback that is based on a scientific approach of breaking cycles within motor learning and propelling golfers to improve faster.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210810005498/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom